Shuttle Pharmaceuticals Holdings, Inc. 8-K Filing
Ticker: SHPH · Form: 8-K · Filed: Nov 28, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Nov 28, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $20,000, $10,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Shuttle Pharmaceuticals Holdings, Inc. (ticker: SHPH) to the SEC on Nov 28, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00001 (ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar); $20,000 (orber will receive a retention bonus of $20,000 on November 21, 2025, and an additional); $10,000 (on November 21, 2025, and an additional $10,000 on December 4, 2025, subject to applica).
How long is this filing?
Shuttle Pharmaceuticals Holdings, Inc.'s 8-K filing is 2 pages with approximately 706 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 706 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2025-11-28 17:31:14
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
- $20,000 — orber will receive a retention bonus of $20,000 on November 21, 2025, and an additional
- $10,000 — on November 21, 2025, and an additional $10,000 on December 4, 2025, subject to applica
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex10-1.htm (EX-10.1) — 86KB
- 0001493152-25-025430.txt ( ) — 313KB
- shph-20251121.xsd (EX-101.SCH) — 3KB
- shph-20251121_lab.xml (EX-101.LAB) — 33KB
- shph-20251121_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: November 28, 2025 By: /s/ Christopher Cooper Name: Christopher Cooper Title: Interim Chief Executive Officer